Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 101–200 of 1,689
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
“Basic science research has suggested several roles that the ε 4 isoform of apolipoprotein E (ApoE4) may play in augmenting the development of AD.”
InfluentialNeurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
“Roughly, 40–65% of individuals that develop AD carry at least one apoE4 allele, and apoE4 homozygosity increases ones chance of developing AD from 20 to 90% [18].”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
The genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 860
George, J. M., Jin, H., Woods, W. S., & Clayton, D. F. (1995) · Neuron · doi:10.1016/0896-6273(95)90040-3 · Cited by 844
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
Finding genes that underlie complex traits.
Glazier, A. M., Nadeau, J. H., & Aitman, T. J. (2002) · Science · doi:10.1126/science.1076641 · Cited by 855
Cognitive Dysfunction and Diabetes Mellitus
Kodl, C. T., & Seaquist, E. R. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0034 · Cited by 802
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
“The APOE ε4-sex interaction on AD The ε4 allele of the APOE gene is a major genetic risk factor of late-onset AD dementia [121] and is consistently linked with abnormal accumulation of the Ab protein [122].”
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data
the Alzheimer’s Disease Neuroimaging Initiative, E. C., Thompson, P. M., Stein, J. L., Medland, S. E., Hibar, D. P., Vasquez, A. A., Renteria, M. E., Toro, R., Jahanshad, N., Schumann, G., et al. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9269-5 · Cited by 838
“They also have a roughly three-fold increased risk for late-onset AD, for each risk allele they carry (Corder et al. 1993).”
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836
“The ApoE4 allele is a genetic risk factor for sporadic AD (Corder et al., 1993).”
BackgroundA Familial Alzheimer's Disease Locus on Chromosome 1
Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 813
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Amyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Petersen, R. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520400044042 · Cited by 780
Differential Effects of Apolipoproteins E3 and E4 on Neuronal Growth in Vitro
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R. E. (1994) · Science · doi:10.1126/science.8171342 · Cited by 795
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Self-citationThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
“The mean ages of the homozygote, heterozygote, and noncarrier groups were younger than the mean age at clinical onset in each of the respective genetic groups in the original case-control study (14).”
BackgroundApolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
Mendelian Inheritance in Man and Its Online Version, OMIM
McKusick, V. A. (2007) · The American Journal of Human Genetics · doi:10.1086/514346 · Cited by 739
“69,70 In many cases, more than one common disorder is re-lated to the same polymorphic allele.”
Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
TREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735
Miyata, M., & Smith, J. D. (1996) · Nature Genetics · doi:10.1038/ng0996-55 · Cited by 735
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
“Metabolism and ageing Since the discovery of the cholesterol-carrying apolipoprotein E (APOE) as a major risk factor for Alzheimer's disease, there has been a mounting interest in the role of this lipid as a possible pathogenic agen”
BackgroundHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Advanced Maillard reaction end products are associated with Alzheimer disease pathology.
Smith, M. A., Taneda, S., Richey, P. L., Miyata, S., Yan, S. D., Stern, D., Sayre, L. M., Monnier, V. M., & Perry, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5710 · Cited by 714
Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders
Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.013 · Cited by 718
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
“First, the apolipoprotein E4 ( apoE4 ) haplotype is a genetic risk factor for Alzheimer disease and, in transgenic mice, apoE modulates Aβ productio”
BackgroundThe allelic architecture of human disease genes: common disease-common variant... or not?
Pritchard, J. K. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2417 · Cited by 711
“A favourite example used by the CDCV proponents is the APOE locus, where a single common allele (known as e4) increases risk to Alzheimer disease and heart disease (20).”
MethodAPOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707
“In 42 late-onset families in which all individuals 60 years of age or older were analyzed, Corder et al demonstrated that individuals with two ε4 alleles had an increased risk and earlier age of onset than individuals who inherited one ε4 allele (34).”
BackgroundObservation of metastable Aβ amyloid protofibrils by atomic force microscopy
Harper, J. D., Wong, S. S., Lieber, C. M., & Lansbury, P. T. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90255-6 · Cited by 697
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 699
Self-citationThe Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies
Lichtenstein, P., De faire, U., Floderus, B., Svartengren, M., Svedberg, P., & Pedersen, N. L. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01032.x · Cited by 696
“Despite positive linkages to three genes for Alzheimer’s disease (APP, PS-I and PS-II) [85] and the association with the susceptibility gene APO-E [ 86 ] little was known about how important, relatively speaking, genetic effects are for Alzheimer’s disease and other dementias, particularly for sporadic and late-onset…”
BackgroundThe role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701
“However, how ApoE contributes to disease pathogenesis remains unclear (Corder et al. 1993; Schmechel et al. 1993).”
BackgroundMild Cognitive Impairment:An Overview
Petersen, R. C., & Negash, S. (2008) · CNS Spectrums · doi:10.1017/s1092852900016151 · Cited by 667
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Self-citationCholesterol metabolism and homeostasis in the brain
Zhang, J., & Liu, Q. (2015) · Protein & Cell · doi:10.1007/s13238-014-0131-3 · Cited by 686
“ApoE isoform ε4 is the most common risk factor identified so far (Corder et al., 1993). ε4 alleles also correlate with amyloid plaques in Alzheimer patient’s autopsy (Schmechel et al., 1993).”
The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)
Multhaup, G., Schlicksupp, A., Hesse, L., Beher, D., Ruppert, T., Masters, C. L., & Beyreuther, K. (1996) · Science · doi:10.1126/science.271.5254.1406 · Cited by 678
Yankner, B. A., Lu, T., & Loerch, P. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.092044 · Cited by 677
Apolipoprotein E ∈4 Associated With Chronic Traumatic Brain Injury in Boxing
Jordan, B. D. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550020068040 · Cited by 427
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Intake of flavonoids and risk of dementia
Commenges, D., Scotet, V., Renaud, S., Jacqmin-Gadda, H., Barberger-Gateau, P., & Dartigues, J.-F. (2000) · European Journal of Epidemiology · doi:10.1023/a:1007614613771 · Cited by 634
“The allele e4 of the APOE gene has been found to be a risk factor for Alzheimer's disease [1], for other neurologic disorders [2] and for CHD [3].”
Backgroundfor the Multiple Sclerosis Genetics Group, Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop, A., Caillier, S. J., Ban, M., Goris, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2103 · Cited by 657
“Discussion Traditional methods for identifying the genetic basis of complex human disease have often been successful when a single, relatively common locus contributes strongly to the phenotyp”
MethodSelf-citationAssociation Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650
Haines, J. L., Ter-Minassian, M., Bazyk, A., Gusella, J. F., Kim, D. J., Terwedow, H., PericakVance, M. A., Rimmler, J. B., Haynes, C. S., Roses, A. D., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-469 · Cited by 651
Self-citationSex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A., & Bennett, D. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.685 · Cited by 643
Apolipoprotein E in animal models of CNS injury and in alzheimer's disease
Poirier, J. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90156-2 · Cited by 639
Propagation of Tau aggregates and neurodegeneration
Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031153 · Cited by 632
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Protein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625
Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 618
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
“APOE-ε4 alleles are associated with accelerated Aß-deposition and earlier onset and higher risk of developing AD symptoms.(21,23) The cause of AD remains controversial and is incompletely understood.”
Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
Barger, S. W., & Harmon, A. D. (1997) · Nature · doi:10.1038/42257 · Cited by 622
“(when the interaction between ApoE4 and AD is most pronounce”
BackgroundBrain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Mosconi, L., Pupi, A., & De Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 595
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
“The presence of one or two copies of the APOE ε4 allele increased the risk to develop LOAD by a factor 3 up to 15-fold in a dose-dependent manner [66,67].”
Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
“Although APOE was identified as a susceptibility factor for AD over 15 years ago [33], it is still not clear how the e4 variant contributes to disease risk.”
BackgroundSmall, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
Self-citationVascular contributions to cognitive impairment and dementia including Alzheimer's disease
Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603
“Lipid metabolism has long been implicated in AD; APOE is both a known genetic risk factor for late onset AD and is the primary lipid carrier in the brain [38].”
BackgroundIron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
Exercise and the brain: something to chew on
van Praag, H. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.007 · Cited by 599
“For example, Apoliprotein (ApoE)-ε4 allele carriers are considered to be at increased risk for AD [26].”
BackgroundApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
“In one paper, Corder et al.[8], showed that the Estimated Onset of Distribution is shifted to considerably younger ages in AD cases with ε4/4 genotype (50% by age of onset of 66 y/o), than the ε3/4 (50% by 73 y/o) or theε3/3 (50% by 86 y/o), and those without anε4 and with anε2 allele have an even later age of onset.”
BackgroundInfluentialNeurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment
Guillozet, A. L., Weintraub, S., Mash, D. C., & Mesulam, M. M. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.729 · Cited by 584
Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight
Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
“[176] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,”
BackgroundApolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587
“Recently, the missense TREM2-R47H mutation has been identified and validated as a risk variant for LOAD (6, 7, 11, 15–19).”
BackgroundInfluentialTraumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?
Johnson, V. E., Stewart, W., & Smith, D. H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2808 · Cited by 587
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Liang, W. S., Reiman, E. M., Valla, J., Dunckley, T., Beach, T. G., Grover, A., Niedzielko, T. L., Schneider, L. E., Mastroeni, D., Caselli, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709259105 · Cited by 585
“The regional pattern of underexpression in the genes encoding ETC subunits, which have been validated here with Western blots, corresponds to the regional pattern of CMRgI reductions observed in PET studies of patients with AD (28, 41–45) such that the PCC and precuneus are preferentially affected in AD (11, 16, 17, 1…”
BackgroundSelf-citationApolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583
Functional brain connectivity using fMRI in aging and Alzheimer’s disease
Dennis, E. L., & Thompson, P. M. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9249-6 · Cited by 583
“2009) and genetic factors such as APOE genotype (Corder et al. 1993).”
InfluentialPlasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800069-jlr200 · Cited by 580
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“It has been identified that APOEε4 is a major risk factor associated with late onset FAD than ε3 and ε2 (Corder et al., 1993; Saunders, 2000).”
InfluentialTDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
Brown, A.-L., Wilkins, O. G., Keuss, M. J., Kargbo-Hill, S. E., Zanovello, M., Lee, W. C., Bampton, A., Lee, F. C. Y., Masino, L., Qi, Y. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04436-3 · Cited by 529
“Any reason to include Kruskal-Wallis test results in FigureS4 (A,B), but not in Figure 4A (labeled with “Wilcoxon-Test” instead)?”
Sklar, P., Gabriel, S. B., McInnis, M. G., Bennett, P., Lim, Y.-M., Tsan, G., Schaffner, S., Kirov, G., Jones, I., Owen, M., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001058 · Cited by 567
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
“The APOE4 allele also drives the age at onset down such that APOE4 carriers are, on average, about 12 years younger than non-carriers (Corder et al., 1993; Roses, 1996).”
Self-reported sleep and β-amyloid deposition in community-dwelling older adults
Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., Zhou, Y., Wong, D. F., Ferrucci, L., & Resnick, S. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4258 · Cited by 570
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Progress and promise of genome-wide association studies for human complex trait genetics
Stranger, B. E., Stahl, E. A., & Raj, T. (2011) · Genetics · doi:10.1534/genetics.110.120907 · Cited by 567
“…that are associated with common disease variation were identified in early linkage/candidate gene studies, e.g., Factor VLeiden in deep venous thrombosis (Bertina et al. 1994), the APOEe-4 allele in Alzheimer’s disease (Corder et al. 1993), and PPARg in type 2 diabetes (Altshuler et al. 2000a).”
BackgroundThe road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
“Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition.”
BackgroundInfluential
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.